← Eichor
Condition: Classical Hodgkin Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Classical Hodgkin Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Phase 2/Phase 3 · 1 location(s) · Children's Cancer Group, China · NCT06563245Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Phase 2 · 18 location(s) · Canadian Cancer Trials Group · NCT05180097Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07275216PD-1 Inhibitors Maintenance for cHL Post-autoHCT
Phase 2 · 4 location(s) · St. Petersburg State Pavlov Medical University · NCT06812858Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
Phase 2 · 1 location(s) · University of Cologne · NCT04837859A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 · 407 location(s) · National Cancer Institute (NCI) · NCT05675410A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Phase N/A · 32 location(s) · Children's Oncology Group · NCT05705531Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
NA · 1 location(s) · Jessica Mezzanotte Sharpe · NCT07555210Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transpla
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06393361MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT06377540Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Phase 2 · 5 location(s) · City of Hope Medical Center · NCT04561206A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT06642792Treatment for Classical Hodgkin Lymphoma in Children and Adolescents
NA · 1 location(s) · GALIA AVRAHAMI · NCT02797717Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT04510636Immunotherapy in Lymphoma
Phase N/A · 2 location(s) · Sung-Soo Park · NCT06796517Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT04288726Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05949931A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNO
Phase 1/Phase 2 · 16 location(s) · Merck Sharp & Dohme LLC · NCT02332668Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R)
Phase 2 · 1 location(s) · University of Washington · NCT07097363Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06848569First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
Phase 3 · 2 location(s) · State Budgetary Healthcare Institution, National Medical Sur · NCT04638790Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1/Phase 2 · 6 location(s) · Veronika Bachanova · NCT03681561Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Phase 2 · 1 location(s) · Navy General Hospital, Beijing · NCT06190067A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-
Phase 3 · 1 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT06170489Liquid Biopsy in Mature B-cell Tumors
Phase N/A · 1 location(s) · Oncology Institute of Southern Switzerland · NCT03280394Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
Phase 2 · 1 location(s) · University of Cologne · NCT04838652Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
NA · 40 location(s) · Fondazione Italiana Linfomi - ETS · NCT05934084Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Ho
Phase 2 · 6 location(s) · University of Washington · NCT06745076Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated W
Phase 2 · 2 location(s) · Emory University · NCT05039073Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
Phase N/A · 12 location(s) · Azienda USL Reggio Emilia - IRCCS · NCT06822855
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.